Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Featured Story Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorWritten by Jeffrey Neal Johnson. Article Posted: 2/24/2026. 
Key Points - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of approximately $245 per share, creating a divergence that has caught Wall Street's attention. This rally undercuts the common perception of the healthcare giant as a slow-moving, boring stock. Over the last 30 days, shares have climbed roughly 14%, significantly outperforming the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, predictable cash flow, and operational execution. For investors watching the ticker today, Feb. 24, 2026, it is important to note a specific calendar event: today is the ex-dividend date for Johnson & Johnson. The stock price will likely dip by the amount of the upcoming dividend payment, $1.30 per share. That is a mechanical market adjustment, not a signal about business performance. For income-focused investors, this technical dip often represents an attractive entry point rather than a trigger to sell. 64 Years of Unbroken Growth The central case for holding Johnson & Johnson during turbulent markets is its financial stability and role as a portfolio stabilizer. The company belongs to an elite group of equities known as Dividend Kings, firms that have increased their dividend payout for at least 50 consecutive years. Johnson & Johnson has now raised its dividend for 64 consecutive years, a record that spans multiple recessions, market crashes, and geopolitical shocks. That reliability is rare in a market still fixated on speculative growth. Currently, the stock yields about 2.12%, based on an annual payout of $5.20 per share. While higher yields exist in the bond market or in riskier sectors, J&J's appeal is the blend of yield, growth potential and safety. Management projects free cash flow of roughly $21 billion in 2026, a liquidity cushion that helps fund dividends, R&D and legal liabilities without heavy borrowing. For risk-averse investors, another compelling metric is the stock's Beta, which measures how much a stock moves compared to the overall market (S&P 500). A Beta of 1.0 means the stock moves in step with the market. Johnson & Johnson's Beta is just 0.35, indicating it has historically been about 65% less volatile than the broader market. When tech names swing wildly, J&J tends to hold ground, acting as a mathematical shock absorber in a tech-heavy portfolio. Beyond the Patent Cliff: The Road to $100 Billion Safe stocks are often assumed to be low-growth. Johnson & Johnson is disproving that by executing a strategic pivot. Management has issued strong guidance for 2026, projecting full-year revenue to surpass the $100 billion mark for the first time in company history, along with adjusted EPS of about $11.53. That growth reflects a successful reinvention of its pharmaceutical division, now branded as Innovative Medicine. Concerns over a patent cliff — notably for Stelara, which lost exclusivity in 2025 — have been offset by the rise of new blockbusters. Two key assets are underpinning this resilience: - Darzalex: This oncology drug generates roughly $14 billion in annual sales and has become a cornerstone therapy in multiple myeloma care.
- Tremfya: Positioned to succeed Stelara in immunology, Tremfya recently reported strong three-year remission data in Ulcerative Colitis, reinforcing J&J's ability to defend market share amid competition.
The Tech in MedTech: High-Margin Technologies Growth extends beyond pharmaceuticals into the MedTech division, which has refocused on higher-growth, higher-margin technologies. A notable example is the integration of Shockwave Medical, acquired to modernize J&J's cardiovascular portfolio. Shockwave's intravascular lithotripsy (IVL) uses sonic pressure waves to break up calcified plaque in arteries — conceptually similar to how kidney stones are treated — and represents a meaningful upgrade over traditional angioplasty approaches. Owning that technology gives Johnson & Johnson a high-growth asset that complements its broader cardiovascular and surgical businesses. The company is also pushing into robotics. The submission of its Ottava robotic surgical system for FDA review signals intent to compete in the expanding soft-tissue robotics market. These devices carry higher profit margins and foster long-term, "sticky" relationships with hospital systems, providing an earnings tailwind beyond consumables and basic surgical tools. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is reshaping the corporate portfolio. A major development is the potential separation or sale of the DePuy Synthes orthopedics business. While originally planned as a spin-off, recent reports suggest the company is exploring a large-scale sale of the asset. Divesting the orthopedics unit would be a classic addition-by-subtraction move. Orthopedics is relatively mature and lower-growth compared with booming fields such as oncology and advanced cardiovascular devices. Removing that slower business could lift revenue growth rates and margins. A sale would also generate a significant lump-sum cash inflow, providing capital for acquisitions, debt reduction, or share buybacks. Addressing legal risks remains essential. J&J still faces litigation over talc products, including a recent $1.5 billion verdict, and a commercial lawsuit from Bayer over marketing claims for prostate cancer drugs has added noise to the news cycle. Nevertheless, the market's recent rally suggests investors are looking past headlines. With more than $20 billion in cash and marketable securities, the potential proceeds from an orthopedics sale, and roughly $21 billion in projected free cash flow, Johnson & Johnson appears well-positioned to absorb legal settlements without threatening its dividend or operations. That financial depth turns legal exposure into a manageable line item rather than an existential risk. Capital Preservation With Upside Johnson & Johnson has evolved from a sprawling conglomerate into a more focused, high-tech healthcare company. By spinning off its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, the company is streamlining to concentrate on high-growth opportunities in pharmaceuticals and medical technology. Although J&J is no longer a bargain-bin value play, trading near all-time highs, it offers a differentiated mix of capital preservation and upside that is hard to find elsewhere: a 64-year dividend growth streak, a low-volatility profile, and a clear path toward $100 billion in revenue. For investors tired of the technology sector's unpredictability, Johnson & Johnson demonstrates that, in the current market, boring can be both beautiful and profitable.
| 
